evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

145 questions · 145 findings · 10 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 48 · 33.1%GRADE not reported 1 · 0.7%Very low 23 · 15.9%Low 49 · 33.8%Moderate 15 · 10.3%High 9 · 6.2%

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

Worsening of clinical status (expressed as new need for IMV, admission to ICU, or death by day 28) · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in worsening of clinical status (expressed as new need for IMV,… compared with saline placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care

All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Summary of findings table ‐ Corticosteroids plus standard care probably leads to lower all‐cause mortality up to 30 days compared with standard care (plus/minus placebo) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Methylprednisolone vs dexamethasone

Clinical improvement: discharged alive ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Methylprednisolone vs dexamethasone

Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Methylprednisolone vs dexamethasone

Hospital‐acquired infections ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

Clinical improvement: discharged alive ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in clinical improvement: discharged alive ( compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care

All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ Corticosteroids plus standard care changes all‐cause mortality up to 120 days compared with standard care (plus/minus placebo) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care

Clinical improvement: discharged alive ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Summary of findings table ‐ Corticosteroids plus standard care may leads to higher clinical improvement: discharged alive ( compared with standard care (plus/minus placebo) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care

Clinical worsening: new need for invasive mechanical ventilation or death · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Summary of findings table ‐ Corticosteroids plus standard care showed no clear difference in clinical worsening: new need for invasive mechanical ventilation or… compared with standard care (plus/minus placebo) (low certainty).

1 finding from 1 review